Accessibility Menu
Ernexa Therapeutics logo

Ernexa Therapeutics(NASDAQ) ERNA

Current Price$4.46
Market Cap$5.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-91%
1 Month-27%
Ernexa Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.542026-07-21
Ernexa Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-25.08%USD 6.062026-07-14
1 month-26.77%USD 6.202026-06-18
3 month-6.3%USD 4.852026-04-22
Year to date-84.87%USD 30.002025-12-31
1 year-90.73%USD 49.002025-07-21
3 year-99.56%USD 1,042.502023-07-21
5 year-99.99%USD 90,300.002021-07-22
Since inception-99.99%USD 35,653.482021-03-26

Ernexa Therapeutics Financials at a Glance

Market Cap

$5.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.39M

EPS (TTM)

-$30.72

P/E Ratio

-0.15

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$4.46

Volume

1,125

Open

$5.21

Previous Close

$4.54

Daily Range

$4.46 - $5.42

52-Week Range

$3.18 - $71.50

Estimated Earnings Date

Aug 12, 2026

ERNA News

A researcher studying a sample in a petri dish

Why Brooklyn ImmunoTherapeutics Crushed the Market Today

Eric VolkmanJun 14, 2021
rocket

Why Brooklyn ImmunoTherapeutics Stock Crushed It in April

George Budwell, PhDMay 8, 2021
GettyImages-1169172674

Up 1,300% in the Past Month, Is This Mysterious Biotech a Buy?

Zhiyuan SunMay 5, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ernexa Therapeutics

Ernexa develops cell-based therapies for cancer and autoimmune diseases. Its main products aim to help patients with ovarian cancer and rheumatoid arthritis. These therapies use engineered cells to target disease processes in the body.

What’s in the Ernexa Toolbox?

  • ERNA-101 (Ovarian Cancer): Cell therapy designed for patients with treatment-resistant ovarian cancer. 0% of 2025 revenue.
  • ERNA-201 (Rheumatoid Arthritis): Cell therapy aimed at reducing inflammation in autoimmune disease. 0% of 2025 revenue.
  • iMSC Platform: Technology for producing off-the-shelf cell therapies from stem cells. 0% of 2025 revenue.
  • Licensing Activities: Exclusive rights to technology from Factor Bioscience for cancer and autoimmune disease. 0% of 2025 revenue.
  • Research Services: Preclinical research and development, with no commercial sales in 2025.

Growth and Expansion: The Ernexa Adventure

  • Changed name from Eterna to Ernexa in March 2025.
  • Signed exclusive license with Factor Bioscience in September 2024 for cell therapy technology.
  • Entered manufacturing agreement with Cellipont Bioservices in October 2025.
  • Joined Japan External Trade Organization program in 2025 for market entry in Japan.
  • Raised $10.5 million in a public offering in February 2026 to fund operations.

What Makes Ernexa Stand Out?

Ernexa focuses on scalable, off-the-shelf cell therapies using induced stem cells. Its business model relies on licensing, partnerships, and research grants. The company holds exclusive rights to a broad patent portfolio for its technology.

Five Things You Need to Know

  • Revenue was $0 in 2025, down 100% from 2024.
  • Net loss was $14.1 million in 2025, improved 68% from 2024.
  • Cash used in operations was $7.0 million in 2025, down 56% from 2024.
  • Cash balance was $1.9 million at December 31, 2025.

Bottom Line

Ernexa has shifted to a research-focused model with no current product sales. The company’s future depends on partnerships, funding, and successful development of its cell therapy pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Sanjeev Luther, MBA

Website

www.ernexatx.com

Headquarters

Cambridge, MA 92121, US

ERNA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-263.68%

Return on Capital

-322.35%

Return on Assets

-108.01%

Earnings Yield

-6.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.17M

Volume

1.13K

Avg. Volume

2.08M

Financials (TTM)

Gross Profit

-$86.00K

Operating Income

-$10.13M

EBITDA

-$16.54M

Operating Cash Flow

-$7.22M

Capital Expenditure

-$39.00K

Free Cash Flow

-$7.26M

Cash & ST Invst.

$9.18M

Total Debt

$389.00K

Ernexa Therapeutics Performance Analysis

Ernexa Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 68,000N/A
20242024-12-31USD 582,000755.9%
20252025-12-31USD 0N/A
Ernexa Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Ernexa Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3,022.98-85.8%
20232023-12-31USD -1,530.20-49.4%
20242024-12-31USD -1,224.31-20.0%
20252025-12-31USD -55.89-95.4%
Ernexa Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-306.7%
Q32025-09-3075.4%
Q42025-12-31-26.7%
Q12026-03-31-46.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$86.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.06M

N/A

Employees

5

N/A

Net Income

-$5.51M

+32.9%

EBITDA

-$5.46M

+32.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$9.18M

+378.5%

Total Debt

$389.00K

-86.5%

Accounts Receivable

$95.00K

-39.1%

Inventory

$0.00

N/A

Long Term Debt

$226.00K

-46.1%

Short Term Debt

$163.00K

-93.4%

Return on Assets

-1.08%

N/A

Return on Invested Capital

-1.43%

N/A

Free Cash Flow

-$2.27M

-9.7%

Operating Cash Flow

-$2.26M

-9.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DWTXDogwood Therapeutics, Inc.
$1.40+1.45%
AEMDAethlon Medical, Inc.
$0.61+1.40%
OSRHOSR Holdings, Inc.
$0.44-5.47%
MBRXMoleculin Biotech, Inc.
$2.15+0.47%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.14+0.24%
SKHYSK Hynix
$171.94+0.14%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.31-0.06%
NOKNokia
$10.63+0.05%

Questions About ERNA

What is the current price of Ernexa Therapeutics?

Ernexa Therapeutics is trading at $4.54 per share.

What is the 52-week range for Ernexa Therapeutics?

Over the past 52 weeks, Ernexa Therapeutics has traded between $3.18 and $71.50.

How much debt does Ernexa Therapeutics have?

As of the most recent reporting period, Ernexa Therapeutics reported total debt of $389.00K.

How much cash does Ernexa Therapeutics have on hand?

Ernexa Therapeutics reported $9.18M in cash and cash equivalents in its most recent financial results.

What is Ernexa Therapeutics’s dividend yield?

Ernexa Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services